Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-09-01
|
| Series: | Blood and Lymphatic Cancer : Targets and Therapy |
| Online Access: | https://www.dovepress.com/critical-appraisal-of-belinostat-in-the-management-of-t-cell-lymphoma--peer-reviewed-article-BLCTT |